ID: MRFR/Pharma/1097-CR | August 2017 | Region: Global | 108 Pages
The anti-fungal treatment market is expected to cross USD 25,764.67 million by 2027 at a CAGR of 6.35%.
$25,764.67 Million
6.35%
North America
2020-2027
The antifungal treatment market size was valued USD 16.60 billion in 2020 and is expected to cross USD 25,764.67 million by 2027 at a CAGR of 6.35%. Antifungal treatment is known as antimycotic treatment which is a pharmaceutical fungicide or fungistatic applied to treat and protect mycoses such as ringworm, candidiasis, cryptococcal meningitis, and others. There are various antifungal drugs obtainable to fight fungal infections. Antifungal drugs are available in multiple types. They can also be given orally, as a topical treatment, or via IV. The development of the market for antifungal treatment is mainly fueled by the growth in incidences of fungal and nosocomial infections. However, a surge in initiatives by people and private organizations to spread consciousness about the myriad of fungal infections is projected to enlarge the global market of antifungal treatment.
Some of the key players in this market are Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany)
Segments The global antifungal treatment market has been segmented on the basis of drugs class, which includes azoles, pyrimidines, echinocandins, polyenes, allylamines, and others drugs.
On the basis of therapeutic indication, the market is segmented into systemic, candidiasis, coccidioidomycosis, and cryptococcosis.
On the basis of pathogen, the market is segmented into Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, and others.
On the basis of end users, the market is segmented into hospitals & clinics, dermatology clinics and other users.
Europe is the second largest antifungal treatment market and holds a noticeable share in the global market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities, skilled medical professionals, and adoption of new therapies.
Increasing prevalence of HIV in Asia Pacific region is the key factor for the market growth. Rising awareness about the antifungal treatment and availability of new treatment methods drive the market in Asia Pacific region. In Asia Pacific, the market shows growth opportunities in China and India. China is expected to be the fastest growing market with the CAGR of 5.24% during the forecasted period.
The Middle East & Africa is expected to show the least growth in this market due to some major factors such as lack of awareness about the anti-fungal treatment, limited access and availability of treatment facilities, low income etc.
Key Findings
The report on the Global anti-fungal treatment market of market research future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regionsRecent DevekopmentHowever, a rise in the prevalence of fungal infections such as candidiasis and aspergillosis is one of the important factors that drive the growth of the antifungal market. Fungal infections are both systematic and superficial infections carries infections of the skin, mouth, and eye. Antifungal treatments with fungicidal activity are mainly applied to treat a wide array of diseases, such as fungal meningitis and ringworm caused by fungal agents. Hence, an increase in cases of patients suffering from nosocomial infections and infection diseases fuels the antifungal treatment market growth. Hence, the rise in cases of infectious disease patients rises the growth of the market. However, an upsurge in the number of treatment approvals gives lucrative opportunities for the enlargement of the world antifungal treatment market during the anticipated period. Area-wise the antifungal treatment industry is analyzed across Europe, North America, LAMEA, and the Asia Pacific which includes India and China.
Intended Audience:
Report Attribute/Metric | Details |
---|---|
Market Size | USD 25,764.67 Million |
CAGR | 6.35% |
Base Year | 2019 |
Forecast Period | 2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
|
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany) |
Key Market Opportunities |
|
Key Market Drivers |
|
The global antifungal treatment market can exhibit 6.35% CAGR from 2020 to 2027.
Bayer AG, Astellas, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi are major players of the global antifungal treatment market.
The Americas is dominating the global market
The global antifungal treatment market is expected to touch a value of USD 25,764.67 million by 2027.